MYRIAD GENETICS INC's ticker is MYGN and the CUSIP is 62855J104. A total of 233 filers reported holding MYRIAD GENETICS INC in Q4 2015. The put-call ratio across all filers is 1.45 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $2,548,000 | -88.1% | 123,800 | -68.2% | 0.20% | -77.4% |
| Q2 2016 | $21,472,000 | +213.8% | 388,978 | +112.8% | 0.90% | +287.6% |
| Q1 2016 | $6,842,000 | -20.7% | 182,774 | -8.6% | 0.23% | -15.0% |
| Q4 2015 | $8,632,000 | -7.9% | 200,000 | -20.0% | 0.27% | +32.4% |
| Q3 2015 | $9,370,000 | -42.0% | 250,000 | -47.4% | 0.21% | -35.5% |
| Q2 2015 | $16,145,000 | -4.0% | 475,000 | 0.0% | 0.32% | -6.4% |
| Q1 2015 | $16,815,000 | +3.9% | 475,000 | 0.0% | 0.34% | +1.8% |
| Q4 2014 | $16,178,000 | -11.7% | 475,000 | 0.0% | 0.34% | -19.4% |
| Q3 2014 | $18,323,000 | -5.8% | 475,000 | -5.0% | 0.42% | -4.1% |
| Q2 2014 | $19,460,000 | -65.7% | 500,000 | -69.8% | 0.44% | -64.5% |
| Q1 2014 | $56,680,000 | +51.8% | 1,657,700 | -6.9% | 1.23% | +48.8% |
| Q4 2013 | $37,350,000 | -10.7% | 1,780,200 | 0.0% | 0.83% | -18.3% |
| Q3 2013 | $41,836,000 | -12.5% | 1,780,200 | 0.0% | 1.01% | -18.7% |
| Q2 2013 | $47,837,000 | – | 1,780,200 | – | 1.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,750,000 | $75,900,000 | 2.61% |
| PFM Health Sciences, LP | 2,025,681 | $55,909,000 | 1.90% |
| Tieton Capital Management, LLC | 118,456 | $3,269,000 | 1.83% |
| Altium Capital Management LP | 190,000 | $5,244,000 | 1.45% |
| DISCIPLINED GROWTH INVESTORS INC /MN | 1,846,490 | $50,963,000 | 1.03% |
| EARNEST PARTNERS LLC | 6,316,365 | $174,332,000 | 1.01% |
| Glenview Capital Management | 1,679,747 | $46,361,000 | 0.99% |
| Zebra Capital Management LLC | 14,209 | $392,000 | 0.63% |
| AIMZ Investment Advisors, LLC | 44,185 | $1,220,000 | 0.48% |
| Phocas Financial Corp. | 132,101 | $3,646,000 | 0.46% |